🔗 Share this article

As the US continues making sweeping revisions to its vaccination guidelines, one figure has emerged in a surprising turn: Høeg, a US-based physician and epidemiologist who initially gained attention by questioning Covid shots in the global health crisis and has focused upon potential deaths after Covid vaccination in her brief position at the FDA.

Planned Overhauls to Childhood Immunization Program

Health officials were set to announce major changes to the pediatric vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a major change that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to present at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the FDA

This interim role may indicate a closer partnership between the drug and biologics branches as Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has often pushed for discontinuing specific pediatric immunization guidelines in the US to become more like Denmark, a society with nationalized medicine and a population roughly the size of Wisconsin’s.

So far statements, she has kept her attention on vaccination policy – usually the responsibility of Prasad, director of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Qualifications

The appointee has no obvious background in medication creation, regulation or management, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She appears not to have the necessary background” for leading the CDER, stated Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a large organization. She lacks background in industry regulation.”

Previous heads of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, said a former acting FDA commissioner. “Frankly, she lacks the type of experience that former directors who led the center have had.”

The drug center has an immense range of responsibilities at the FDA, she emphasized.

“The public just zeroes in on the new drug program, but the generic program approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those must be looked after,” she noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial management component to the role, which manages over 5,000 employees. “It is a massive management job, if you execute it properly,” the former official added.

Agency Reaction and Disputed Initiatives

In response to questions about Dr. Høeg's qualifications and whether this selection represents greater collaboration among FDA leaders on vaccines, a spokesperson said that the “inquiries stem from inaccurate premises”.

“Her experience aligns with the duties of her role,” the spokesperson said, noting the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg inherits the agency head's new priority voucher program, a controversial one-day therapy clearance system that reportedly concerned her preceding directors. “How are these drugs being picked for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of lack of transparency happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer oversight of all drugs, with the exception of vaccines.”

Established Track Record on Vaccines

With vaccines, Høeg has a more documented, if problematic, past, some experts said. She released a study using unconfirmed crowd-sourced reports to estimate the rate of heart inflammation after COVID-19 vaccination. She counseled the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming federal leadership encompassed altering regulations for novel immunizations and halting “unnecessary” immunizations, she stated after the election on a podcast. At the FDA, Høeg has allegedly suggested barring teenage boys from getting Covid vaccinations.

“She’s an thorough true believer who starts off with her preconceived notions and works backwards to accommodate the evidence in a extremely deceptive, dishonest manner,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of fellow skeptics, {like|